US 2014/0228352 A1Published application

Heterocyclic compound

AssigneeTakeda Pharmaceutical Company Limited

InventorsMisaki HOMMA, Toru MIYAZAKI, Yuya OGURO, Osamu KURASAWA

Life of this patent

Estimating the term…

Abstract

Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.

Claims11

Dependent claims

1-28. (canceled)

Dependencies are inferred from the claim text.

Facts

Application: 14/223,259Filed 24 Mar 2014
Priority: JP 2010-03189917 Feb 2010
Published: 14 Aug 2014
Term ends: Not estimatedThe source records don’t support an estimate.

Classification13 codes

A61K 31/519
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: ortho- or peri-condensed with heterocyclic rings
A61K 31/5377
1,4-Oxazines, e.g. morpholine: not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/541
Having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame: non-condensed thiazines containing…
A61K 31/55
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having seven-membered rings, e.g. azelastine, pentylenetetrazole

Family

Application13/578,959Continuation · filed 9 Oct 2012
Application14/223,259Continuation
US 2013/0029969 A1Published application
US 8,722,660 B2Related patent
US 8,921,354 B2Related patent
US 2014/0228352 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results